(Q39698180)

14 September 2017

title

EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor (English)

1 reference

14 September 2017

1 reference

1 reference

L Su

1

1 reference

14 September 2017

H Cheng

2

1 reference

14 September 2017

A V Sampaio

3

1 reference

14 September 2017

T O Nielsen

4

1 reference

14 September 2017

T M Underhill

5

1 reference

14 September 2017

language of work or name

English

0 references

publication date

31 May 2010

1 reference

14 September 2017

1 reference

14 September 2017

volume

29

1 reference

14 September 2017

issue

30

1 reference

14 September 2017

page(s)

4352-4361

1 reference

Molecular characterization of synovial sarcoma in children and adolescents: evidence of akt activation

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Down-regulation of PTEN expression due to loss of promoter activity in human hepatocellular carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Anticancer activities of histone deacetylase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

The SYT protein involved in the t(X;18) synovial sarcoma translocation is a transcriptional activator localised in nuclear bodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Inhibition of cell growth by EGR-1 in human primary cultures from malignant glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

PTEN/AKT pathway involved in histone deacetylases inhibitor induced cell growth inhibition and apoptosis of oral squamous cell carcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Phospholipase D prevents etoposide-induced apoptosis by inhibiting the expression of early growth response-1 and phosphatase and tensin homologue deleted on chromosome 10.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

The transcription factor EGR-1 suppresses transformation of human fibrosarcoma HT1080 cells by coordinated induction of transforming growth factor-beta1, fibronectin, and plasminogen activator inhibitor-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Analysis of transforming activity of human synovial sarcoma-associated chimeric protein SYT-SSX1 bound to chromatin remodeling factor hBRM/hSNF2 alpha

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Early growth response-1-dependent apoptosis is mediated by p53.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Histone deacetylase inhibitor trichostatin a potentiates doxorubicin-induced apoptosis by up-regulating PTEN expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Site-specific acetylation of p53 directs selective transcription complex assembly.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

SSX and the synovial-sarcoma-specific chimaeric protein SYT-SSX co-localize with the human Polycomb group complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

HDAC inhibitor-based therapies and haematological malignancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Functional domains of the SYT and SYT-SSX synovial sarcoma translocation proteins and co-localization with the SNF protein BRM in the nucleus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Egr1 promotes growth and survival of prostate cancer cells. Identification of novel Egr1 target genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Coactivating factors p300 and CBP are transcriptionally crossregulated by Egr1 in prostate cells, leading to divergent responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

PTEN regulation by Akt-EGR1-ARF-PTEN axis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

31 March 2020

Identifiers

DOI

10.1038/ONC.2010.204

1 reference

Dimensions Publication ID

14 September 2017

1021082728

0 references

1 reference